Oncology

Isaac Brownell, MD, PhD, of Memorial Sloan-Kettering Cancer Center, discusses means of preventing and detecting skin cancers, including basal cell carcinoma, squamous cell carcinoma, and melanoma.

When compared with traditional treatments, biologic therapies for RA were found to not be associated with an increased risk of cancer.

Breakthrough cancer pain-episodes of intense pain experienced by many cancer patients despite around-the-clock treatment with opioids-can be effectively managed with a fentanyl-based oral spray.

Pharmacists can close the information gap for patients with cancer at every stage and provide valuable counseling and support.

Checking for omissions, duplications, dosing errors, compliance, and drug interactions by an inpatient or outpatient pharmacy team can prevent errors and ensure that a patient's medications are accurate and safe.

Pharmacists can and should play a vital role in educating patients about prostate specific antigen testing and current knowledge about prostate cancer.

New antineoplastic agents approved by the FDA for a variety of cancers advance drug therapy as more research spurs the fast pace of change in oncology.

The FDA approved Genetech's Erivedge (vismodegib) capsules for the treatment of adult patients with metastatic basal cell carcinoma(BCC) or with locally advanced BCC that has recurred following surgery, and for patients who are not candidates for radiation.

Staying the course with quality, integrity, and true customer partnerships.

Continuing medical education company PER hosts congress conducted by leading faculty.

Continuing Medical Education Company-PER-Hosts Congress Conducted by Leading Faculty

The United States Food and Drug Administration recently approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.

The United States Food and Drug Administration today approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least 2 prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy.

An analysis of the top 200 drugs by prescriptions dispensed and total sales reveals key trends in today's pharmaceutical market.

This article-written by Michael Marlan Mohundro, PharmD; and Brice Labruzzo Mohundro, PharmD-highlights the multiple available regimens for patients with relapsed or refractory myelomas as well as new treatments that are currently being investigated in clinical trials.

Specialty Pharmacy Times spoke to Milayna Subar, MD, vice president and national practice leader in oncology for the Oncology Therapeutic Resource Center (TRC) at Express Scripts, to learn more about how access to clinical practice guidelines in oncology can help shape the complex landscape of cancer treatment.

This continuing education activity addresses the factors that increase and decrease a woman's risk for breast cancer, and includes information for pharmacists to help provide evidence-based counseling on preventative measures.

The FDA approved Genentech, Inc's pertuzumab injection (Perjeta) for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Girls who received mantle radiation for childhood cancer were found to be at elevated risk for secondary breast cancer later in life.

Afatinib shows promise as a treatment for patients with advanced lung adenocarcinomas who tested positive for EGFR mutations.